- Home
- CHRS vs DRTS Comparison
CHRS vs DRTS Comparison
Compare CHRS & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- DRTS
- Stock Information
- Founded
- CHRS 2010
- DRTS 2015
- Country
- CHRS United States
- DRTS Israel
- Employees
- CHRS N/A
- DRTS N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- DRTS Medical/Dental Instruments
- Sector
- CHRS Health Care
- DRTS Health Care
- Exchange
- CHRS Nasdaq
- DRTS Nasdaq
- Market Cap
- CHRS 191.3M
- DRTS 159.1M
- IPO Year
- CHRS 2014
- DRTS N/A
- Fundamental
- Price
- CHRS $1.32
- DRTS $4.05
- Analyst Decision
- CHRS Strong Buy
- DRTS Strong Buy
- Analyst Count
- CHRS 4
- DRTS 2
- Target Price
- CHRS $5.38
- DRTS $8.00
- AVG Volume (30 Days)
- CHRS 2.0M
- DRTS 100.7K
- Earning Date
- CHRS 03-12-2025
- DRTS 03-06-2025
- Dividend Yield
- CHRS N/A
- DRTS N/A
- EPS Growth
- CHRS N/A
- DRTS N/A
- EPS
- CHRS N/A
- DRTS N/A
- Revenue
- CHRS $304,340,000.00
- DRTS N/A
- Revenue This Year
- CHRS $2.47
- DRTS N/A
- Revenue Next Year
- CHRS N/A
- DRTS N/A
- P/E Ratio
- CHRS N/A
- DRTS N/A
- Revenue Growth
- CHRS 44.19
- DRTS N/A
- 52 Week Low
- CHRS $0.66
- DRTS $1.75
- 52 Week High
- CHRS $2.87
- DRTS $4.08
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- DRTS 74.41
- Support Level
- CHRS $1.38
- DRTS $3.20
- Resistance Level
- CHRS $1.60
- DRTS $4.08
- Average True Range (ATR)
- CHRS 0.12
- DRTS 0.23
- MACD
- CHRS -0.03
- DRTS 0.06
- Stochastic Oscillator
- CHRS 1.10
- DRTS 97.20
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.